Nuclear Brachyury Expression Is Consistent in Chordoma, Common in Germ Cell Tumors and Small Cell Carcinomas, and Rare in Other Carcinomas and Sarcomas: An Immunohistochemical Study of 5229 Cases
about
Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury.Metastatic Chordoma: A Diagnostic Challenge on Fine Needle AspirationEnhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab.Predicting clinical outcomes in chordoma patients receiving immunotherapy: a comparison between volumetric segmentation and RECISTRecent advances in understanding and managing chordomas.Genetic aberrations and molecular biology of skull base chordoma and chondrosarcoma.Development of Cancer Vaccines Targeting Brachyury, a Transcription Factor Associated with Tumor Epithelial-Mesenchymal Transition.Brachyury, a vaccine target, is overexpressed in triple-negative breast cancer.Phase I Study of a Poxviral TRICOM-Based Vaccine Directed Against the Transcription Factor Brachyury.Brachyury-YAP Regulatory Axis Drives Stemness and Growth in Cancer.Chordoma of the Head and Neck: A Review.Immunophenotypic features of dedifferentiated skull base chordoma: An insight into the intratumoural heterogeneity.Chordoma: The Quest for Better Treatment Options.[Notochordal tumors : Benign notochordal tumors and chordomas].The embryonic transcription factor Brachyury confers chordoma chemoresistance via upregulating CA9.Loss of the Cyclin-Dependent Kinase Inhibitor 1 in the Context of Brachyury-Mediated Phenotypic Plasticity Drives Tumor Resistance to Immune Attack.An update on mesenchymal tumours of the orbit with an emphasis on the value of molecular/cytogenetic testing.
P2860
Q33275671-A03337DD-A7C6-4F2B-AF1C-7E3CF36E222FQ33275914-EDF719C2-E2A8-4D57-9091-8D4BB1B397F7Q33276035-A0460A5E-B8ED-4D50-AAC5-9B9380EBA849Q33276181-939B7364-4DD7-4BBB-B9FC-6DDB5568F097Q33276348-A8FEFBF7-E41E-4625-A3F3-4B3B54BB955EQ33276468-8E9EEEAB-7ACF-4A17-B606-DDB595CD915FQ39142273-12ED68A8-D2E6-4AD1-956A-203C47A39D9EQ39435498-BD102425-3BF7-442D-A449-1F8C2AD4F4A5Q40074028-348300BA-5890-4CAB-96E6-EA6F51279751Q42260320-C852286E-17B8-452E-AE75-07AB8B6B3F79Q48241791-1B8AA683-5775-47E0-80E2-F16A147F925BQ50128933-E6E29F53-62C2-4E34-8877-C06E3EFD1654Q51034581-27364786-81A8-4113-A829-F8B5E74395D8Q51753901-2EDFB1F5-84DE-4C56-94FB-EFE3B3A5A402Q53696581-A8635753-FCEF-4ABB-A6D6-54CA3564E5A4Q54974080-7A652540-EEE1-4FBD-8F8A-DA345C529CACQ55317217-5F40AFEA-C102-40FA-87D3-C281A6904B50
P2860
Nuclear Brachyury Expression Is Consistent in Chordoma, Common in Germ Cell Tumors and Small Cell Carcinomas, and Rare in Other Carcinomas and Sarcomas: An Immunohistochemical Study of 5229 Cases
description
2015 nî lūn-bûn
@nan
2015 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Nuclear Brachyury Expression I ...... tochemical Study of 5229 Cases
@ast
Nuclear Brachyury Expression I ...... tochemical Study of 5229 Cases
@en
Nuclear Brachyury Expression I ...... ochemical Study of 5229 Cases.
@nl
type
label
Nuclear Brachyury Expression I ...... tochemical Study of 5229 Cases
@ast
Nuclear Brachyury Expression I ...... tochemical Study of 5229 Cases
@en
Nuclear Brachyury Expression I ...... ochemical Study of 5229 Cases.
@nl
prefLabel
Nuclear Brachyury Expression I ...... tochemical Study of 5229 Cases
@ast
Nuclear Brachyury Expression I ...... tochemical Study of 5229 Cases
@en
Nuclear Brachyury Expression I ...... ochemical Study of 5229 Cases.
@nl
P2093
P2860
P1476
Nuclear Brachyury Expression I ...... tochemical Study of 5229 Cases
@en
P2093
Christopher Heery
Claudia Palena
Jeffrey Schlom
Jerzy Lasota
Markku Miettinen
Zengfeng Wang
P2860
P304
P356
10.1097/PAS.0000000000000462
P407
P577
2015-04-04T00:00:00Z